Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, double-blind, randomised, placebo-controlled trial, of oral anticoagulation with apixaban in participants with Systemic Sclerosis-related Pulmonary Arterial Hypertension, measuring time to clinical worsening of Pulmonary Arterial Hypertension.

Next Previous
Search
Trial Profile

A multi-centre, double-blind, randomised, placebo-controlled trial, of oral anticoagulation with apixaban in participants with Systemic Sclerosis-related Pulmonary Arterial Hypertension, measuring time to clinical worsening of Pulmonary Arterial Hypertension.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary)
  • Indications Pulmonary arterial hypertension; Systemic scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPHInX

    • Most Recent Events

    • 16 Sep 2019 Status changed from recruiting to active, no longer recruiting.
    • 02 Apr 2019 Planned End Date changed from 31 Dec 2021 to 31 Jul 2022.
    • 27 Apr 2017 Planned End Date changed from 4 Dec 2017 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top